A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Head and Neck Cancer Clinical Trial

Official title:

A Pilot Study of Radiation De-Escalation for p16 Negative Oropharyngeal Cancer and p16-Negative or Positive Laryngeal and Hypopharyngeal Cancers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05544136
• Other study ID #: 22-227
• Status: Recruiting
• Phase: Phase 2
• Start date: September 12, 2022
• Est. completion date: March 12, 2027

Study information

• Verified date: April 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Kaveh Zakeri, MD
• Phone: 848-225-6435
• Email: ZakeriK[@]mskcc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: March 12, 2027
• Est. primary completion date: March 12, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of SCC of the head and neck (excluding nasopharynx, nasal cavity/paranasal sinus, oral cavity, salivary, thyroid, and cutaneous primary malignancies).

• Any unknown primary SCC of the head and neck with radiographically detectable gross nodes is allowed (core or excisional biopsy acceptable; if excisional biopsy is performed, there must be residual radiographically detectable nodal disease; FNA may be acceptable only with PI and/or co-PI approval)

• If the primary site is oropharynx or unknown primary, P16 IHC must be negative.

• If the primary site is hypopharynx or larynx, any P16 status is acceptable (positive, negative, or unknown). P16 IHC is strongly encouraged when possible.

• Clinical stage T0-3 N1-2C M0 (AJCC 7th edition) without evidence of distant metastasis based on staging FDG PET/CT.

• 18 years of age or older.

• Must not have received prior radiation therapy or chemotherapy for HNC.

• Patients who have had their primary site tumor removed by surgery but still have residual grossly enlarged, radiographically detectable lymph nodes are eligible for this study.

• Karnofsky Performance Status (KPS) = 70.

• CT or MRI of the Neck with and without contrast

o Note: A CT scan of the Neck and/or a PET/CT performed for the purposes of radiation planning may serve as planning tools.

• Adequate hematologic function within 30 days prior to registration, defined as follows:

• White Blood Count (WBC) = 2,000 cells/µL

• Absolute neutrophil count (ANC) = 1,000 cells/mm3

• Platelets = 100,000 cells/mm3

• Hemoglobin = 8.0 g/dL; Note: The use of transfusion or other interventions to achieve Hgb = 8.0 g/dL is acceptable

• Adequate renal function within 30 days prior to registration, defined as follows:

• Serum creatinine < 1.5 mg/dL or creatinine clearance (CrCl) = 50 mL/min determined by 24-hour collection or estimated by Cockcroft-Gault formula: CrCl male = [(140 - age) x (weight in kg)] / [(Serum Cr mg/dL) x (72)] CrCl female = 0.85 x (CrCl male)

• Patients with serum creatinine > 1.5 mg/dL can be eligible for carboplatin-based chemotherapy with approval of co-PI (Dr. Eric Sherman

• Adequate hepatic function within 30 days prior to registration, defined as follows:

• Bilirubin < 2 mg/dL

• AST or ALT < 3 x the upper limit of normal

• Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential.

• The subject/legally authorized representative (LAR) must provide study-specific informed consent prior to study entry.

Exclusion Criteria:

• All nasopharyngeal, nasal cavity/paranasal sinus, oral cavity, salivary gland, thyroid, and cutaneous primary malignancies.

• Any T4 or N3 patients

• Any prior radiotherapy to the head and neck region.

• Any prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different non-H&N cancer is permissible.

• Prior chemotherapy or radiotherapy within the last three years.

• Patients who underwent previous surgical resection for the same disease (except for biopsy or surgery removing primary site tumor but still present with grossly enlarged, radiographically detectable lymph nodes).

• Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years estimated to be = 90%.

• Subjects with simultaneous primary cancers outside of the oropharynx

o Note: Exceptions can be made for patients with simultaneous primaries outside the H&N if determined by the PI/Co-PI that the patient can proceed with protocol activities.

• Pregnant (confirmed by serum b-HCG in women of reproductive age) or breastfeeding.

• Severe, active co-morbidities defined as follows:

• Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.

• Transmural myocardial infarction within the last 6 months.

• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.

• Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration.

• Hepatic Insufficiency resulting in clinical jaundice and/or coagulation defects.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Cancer
• Head and Neck Carcinoma
• Head and Neck Neoplasms
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Diagnostic Test:
• 18F-FMISO PET/CT scan
18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start

Radiation:
• Chemoradiation therapy
18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes). 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes.

Drug:
• Carboplatin
The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants alive post-Chemo Radiation Therapy	The primary objective is to assess the pilot efficacy of RT dose de-escalation to grossly involved lymph nodes for hypoxia negative T0-T3N1-2B HPV- OPC/UPC and HPC/LXC patients. For evaluation on the efficacy of the regimen in this cohort, a simple decision rule will be implemented as follows: If, among the first 10 evaluable patients, we have at least 8 patients who are alive, followed, and have major pathological response on planned neck dissection at 4 months ± 1 month post-CRT, then we will declare the treatment modality using that RT dose has pilot efficacy and will then proceed with treatment at the next de-escalated dose level.	2.5 years

External Links

•   Memorial Sloan Kettering Cancer Center